Treanda Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

B-cell lymphoma with intracellular crystals: a mimic of crystal-storing histiocytosis
A 74-year-old man with chronic kidney disease and splenic marginal zone lymphoma, diagnosed 3 years ago, status post bendamustine and rituximab and now on zanubrutinib due to recurrence, presented with acute kidney injury and proteinuria. On admission, he had a serum creatinine level of 2.7 mg/dl (baseline, ≈1.9 mg/dl), a urine protein-to-creatinine ratio of 5 g/g, and a serum albumin level of 3.2 g/dl. Serum protein electrophoresis showed IgGκ M protein. Serum free light chain ratio was 3.2. (Source: Kidney International)
Source: Kidney International - April 18, 2024 Category: Urology & Nephrology Authors: Michael G. Daniel, Craig R. Soderquist, Satoru Kudose Tags: Nephrology Image Source Type: research

Real ‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy
ConclusionsIn this real-world analysis, 25.2% of patients experienced R/R-DLBCL after 1L with poor outcomes. Given the findings of this study, there is a high unmet need for novel, safe, and effective treatment options for patients with R/R DLBCL. (Source: Cancer Medicine)
Source: Cancer Medicine - April 10, 2024 Category: Cancer & Oncology Authors: Helmneh M. Sineshaw, Christina M. Zettler, Jennifer Prescott, Mahek Garg, Samhita Chakraborty, Eric M. Sarpong, Claire Bai, Andrew J. Belli, Laura L. Fernandes, Ching ‐Kun Wang Tags: RESEARCH ARTICLE Source Type: research

Analysis of Caregiver Burden and Influencing Factors in Autologous Hematopoietic Stem Cell Transplantation Patients with Bendamustine Preconditioning
This study has positive implications for optimizing the implementation of Auto-HSCT therapy.PMID:38581336 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - April 6, 2024 Category: Complementary Medicine Authors: Yanping Chen Yan Zhang Qianqian Chen Source Type: research

Bendamustine/Rituximab
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2024 Category: Drugs & Pharmacology Source Type: research

Antibiotics/bendamustine/rituximab
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2024 Category: Drugs & Pharmacology Source Type: research

Cancers, Vol. 16, Pages 1285: Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study
In conclusion, R-B followed by rituximab maintenance therapy in patients with previously untreated FL resulted in significantly longer PFS than R-CHOP, with older patients also benefiting from this treatment without further toxicity. Adverse events during maintenance were more frequent with R-B without impacting mortality. (Source: Cancers)
Source: Cancers - March 26, 2024 Category: Cancer & Oncology Authors: Mariana Bastos-Oreiro Antonio Gutierrez Almudena Cabero Javier L ópez Paola Villafuerte Ana Jim énez-Ubieto Raquel de O ña Adolfo De la Fuente Bel én Navarro Javier Pe ñalver Pilar Mart ínez Carmen Alonso Mar ía Infante Ra úl Córdoba Blanca Perez Tags: Article Source Type: research

End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial
This study aimed to evaluate the usefulness of end-of-treatment (EOT)-PET for predicting PFS in FL patients in first relapse. EOT-PET examinations were performed between 6 and 8 weeks from the start of the last BR cycle. The primary endpoint was 1-year PFS. Key secondary endpoints were overall response rate (ORR), complete response rate (CRR), and 1-year overall survival (OS). Seventy-five patients were enrolled, and 8 were excluded from analysis. ORR was 86.6% and CRR was 59.7%. One-year PFS was 88.9% (95% confidence interval [CI] 80.7-94.3%) and 1-year OS in 75 patients was 97.3% (95% CI 89.6-99.3%). One-year PFS was sig...
Source: International Journal of Hematology - March 23, 2024 Category: Hematology Authors: Koji Kato Koji Izutsu Momoko Nishikori Hirohiko Shibayama Yoshinobu Maeda Kenichi Yoshimura Ukihide Tateishi Toshihiro Miyamoto Yasufumi Matsuda Jun Ishikawa Shinya Rai Tsutomu Takahashi Takahiro Yamauchi Itaru Matsumura Koichi Akashi Yuzuru Kanakura Junj Source Type: research

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109. Online ahead of print.ABSTRACTNot available.PMID:38497158 | DOI:10.3324/haematol.2023.284109 (Source: Haematologica)
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Emilio Iannitto Simone Ferrero C ôme Bommier Daniela Drandi Martina Ferrante Krimo Bouabdallah Sylvain Carras Guido Gini Vincent Camus Salvatrice Mancuso Luigi Marcheselli Angela Ferrari Michele Merli Benoit Tessoulin Caterina Stelitano Kheira Beldjord G Source Type: research